Tourmaline Bio Statistics
Total Valuation
Tourmaline Bio has a market cap or net worth of $433.83 million. The enterprise value is $175.77 million.
Important Dates
The next estimated earnings date is Monday, May 12, 2025, before market open.
| Earnings Date | May 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Tourmaline Bio has 25.69 million shares outstanding. The number of shares has increased by 433.98% in one year.
| Current Share Class | 25.69M |
| Shares Outstanding | 25.69M |
| Shares Change (YoY) | +433.98% |
| Shares Change (QoQ) | +0.11% |
| Owned by Insiders (%) | 8.43% |
| Owned by Institutions (%) | 66.54% |
| Float | 15.58M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.44 |
| P/TBV Ratio | 1.45 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 30.18, with a Debt / Equity ratio of 0.00.
| Current Ratio | 30.18 |
| Quick Ratio | 28.99 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -28.99% and return on invested capital (ROIC) is -22.18%.
| Return on Equity (ROE) | -28.99% |
| Return on Assets (ROA) | -21.60% |
| Return on Invested Capital (ROIC) | -22.18% |
| Return on Capital Employed (ROCE) | -29.90% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$989,324 |
| Employee Count | 74 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +9.47% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +9.47% |
| 50-Day Moving Average | 14.76 |
| 200-Day Moving Average | 19.13 |
| Relative Strength Index (RSI) | 59.43 |
| Average Volume (20 Days) | 367,844 |
Short Selling Information
The latest short interest is 3.06 million, so 11.92% of the outstanding shares have been sold short.
| Short Interest | 3.06M |
| Short Previous Month | 3.23M |
| Short % of Shares Out | 11.92% |
| Short % of Float | 19.66% |
| Short Ratio (days to cover) | 7.84 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -89.73M |
| Pretax Income | -35.69M |
| Net Income | -73.21M |
| EBITDA | -89.69M |
| EBIT | -89.73M |
| Earnings Per Share (EPS) | -$2.89 |
Full Income StatementBalance Sheet
The company has $258.30 million in cash and $244,000 in debt, giving a net cash position of $258.06 million or $10.05 per share.
| Cash & Cash Equivalents | 258.30M |
| Total Debt | 244,000 |
| Net Cash | 258.06M |
| Net Cash Per Share | $10.05 |
| Equity (Book Value) | 300.05M |
| Book Value Per Share | 11.71 |
| Working Capital | 259.93M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$77.26 million and capital expenditures -$9,000, giving a free cash flow of -$77.27 million.
| Operating Cash Flow | -77.26M |
| Capital Expenditures | -9,000 |
| Free Cash Flow | -77.27M |
| FCF Per Share | -$3.01 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |